CPHI Online Report - Pharma Market Trends 2021

Pharma Market Trends 2021
Twelve pharma market trends we anticipate across 2021 for the drug development, manufacturing and outsourcing sectors.
2020 has been one of the most turbulent years in recent history and has cast a shroud of uncertainty over the future. While pharmaceutical companies have proved instrumental in responding to the pandemic through innovation, collaboration and manufacturing expertise, COVID-19 has also raised fresh challenges for the industry to overcome.
In this trend report, we explore the key opportunities, disruptors and dynamics which the industry will face throughout 2021.
Pharma’s response to the pandemic in terms of vaccines development and distribution of treatments has grabbed the majority of the headlines but the major issues facing the industry are by no means exclusively coronavirus related.
In interviews with key industry experts, this report identifies key trends that we anticipate throughout 2021, as pharmaceutical manufacturing and outsourcing continue to respond not only to the challenges that the ongoing global crisis has presented, but also to evolving obstacles and hurdles that are typical in such a highly-regulated sector.
Key pharma market trends for 2021:
- Supply chain resilience to take precedence over reshoring of active pharmaceutical ingredient manufacturing
- Pandemic accelerates digital transformation of API sourcing and trading
- Suppy chain security and patient centricity focus
- Cure vs. treatment model shifts CDMO contracts from volume to value
- A gradual breakthrough for continuous manufacturing of APIs
- COVID-19 vaccines to take central stage
- Vaccine distribution and roll-out
- Industry fight against antimicrobial resistance to gain prominence
- Enablers of precision medicine: next-generation sequencing
- Continuing consolidation in the pharma contract services sector
- Emerging pharma markets will be key to expansion of pharma and biopharma capabilities
- Rise in biosimilar applications due to patent expiries
Click the link at the bottom of this page to download the complete CPHI Pharma 2021 Trends Report

Related News
-
News CPHI Americas 2025 - From the Floor
Our From the Floor live blog is back in Philadelphia for this year’s CPHI, this time under the new name CPHI Americas to embrace and represent the whole of the pharmaceutical supply chain from north to south.
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.